Pawel Mazur, PhD
Department of Experimental Radiation Oncology, Division of Radiation Oncology
Present Title & Affiliation
Primary Appointment
Associate Professor, Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Experimental Radiation Onc, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2016 | Collegium Medicum - Jagiellonian University, Krakow, PL, Habilitation in Molecular Medicine |
| 2011 | Max Planck Institute of Biochemistry and Technical University, Munich, DE, Ph.D. in Molecular Biology / Cancer Research |
| 2005 | Warsaw University, Warszawa, PL, M.Sc. in Molecular Biology |
| 2003 | Warsaw University, Warszawa, PL, B.Sc. in Molecular Biology |
Postgraduate Training
| 2015-2016 | Instructor, Stanford University, Stanford, California |
| 2011-2015 | Postdoctoral Fellow, Molecular mechanisms of the MAPK signaling regulation in pancreatic cancer, Stanford University, Stanford, California |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - 2022
Extramural Institutional Committee Activities
Academic Committee Member and Reviewer, Institutional Animal Care and Use Committee (IACUC), The University of Texas MD Anderson Cancer Center, 2020 - Present
Committee Member, CPRIT Graduate Scholars Application Review Committee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member of the Senate, Faculty Senate at MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2019 - Present
Committee Member, Academic Review Committee (formerly the Faculty Academic Review Committee) at MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2019 - Present
Committee Member, Academic Committee Member for the New Technology Implementation in Shared Resources Committee, The University of Texas MD Anderson Cancer Center, 2018 - Present
Committee Member, Fellowships and Awards Committee at Graduate School of Biological Science (GSBS), The University of Texas MD Anderson Cancer Center, 2018 - 2019
Academic Committee Member and Reviewer, Institutional Biosafety Committee at MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, 2017 - Present
Honors & Awards
| 2023 | Faculty Scholar Award, MD Anderson Cancer Center |
| 2021 | MD Anderson’s Wall of Science, The University of Texas M. D. Anderson Cancer Center |
| 2020 | The 2020 Wilson S. Stone Memorial Award, The University of Texas M. D. Anderson Cancer Center |
| 2019 | MD Anderson's Wall of Science, The University of Texas M. D. Anderson Cancer Center |
| 2018 - 2020 | Sabin Family Foundation Fellow, The University of Texas M. D. Anderson Cancer Center |
| 2018 | Caroline Craig Augustyn and Damian Augustyn Award in Digestive Cancer Research, American Gastroenterological Association |
| 2017 - 2021 | CPRIT Scholar, Cancer Prevention and Research Institute of Texas |
| 2017 | Rising STARs Award, The University of Texas |
| 2015 | Research Award, Stanford University Department of Pediatrics Annual Retreat |
| 2014 | Research Award, AACR Pancreatic Cancer Meeting |
| 2013 | Selected Talk, Salk Symposium Mechanisms and Models of Cancer |
| 2012 | Postdoctoral Award, Tobacco-Related Disease Research Program |
| 2012 | Postdoctoral Award, Lucile Packard Found for Children's Health & Child Health Research Institute |
| 2011 | Selected Talk, AACR Meeting Frontiers in Basic Cancer Research |
| 2011 | Ph.D. summa cum laude, unanimous Defense Committee congratulations |
| 2011 | Dean's Postdoctoral Fellowship, Stanford University School of Medicine |
| 2010 | AACR Training Award, Translational Cancer Research for Basic Science |
| 2010 | The Hirshberg Research Award, American Pancreatic Association and the Hirshberg Fund |
| 2010 | Research Award, European Association for Cancer Research Annual Meeting |
| 2009 | AACR Training Award, Pathobiology of Cancer |
| 2009 | Deregulation of Transcription in Cancer Award, Keystone Symposia |
| 2005 | M.Sc. summa cum laude, Univeersity of Warsaw |
| 2004 | Burroughs Welcome Fund Award, Cold Spring Harbor Laboratory |
| 2003 | Best Student Award, University of Warsaw and Mayer of Warsaw |
| 2003 | B.Sc. summa cum laude, University of Warsaw |
| 2002 | Dr. M. Kanton Found Award, Bank Pekao-UniCreditGroup |
| 2002 | Global Leader Award, Goldman Sachs Foundation and IIE |
| 2000 - 2005 | Award for Extraordinary Academic Achievements, Ministry of National Education |
| 2000 | First Prize on the European Essay Contest, European Union |
| 1999 - 2000 | President of Poland Award, Extraordinary Academic Achievements |
| 1999 | Prime Minister Award for the Best Student |
| 1999 | Second Prize at the United Nations Essay Contest, The Hague |
| 1999 | Diploma of Laureate, XXIX National Biology Olympiad |
| 1998 - 1999 | First step to Nobel Prize Awards, 6th and 7th International Competition in Physics |
| 1997 - 2000 | Polish Children's Fund Award, Extraordinary Academic Achievements |
| 1997 - 1999 | Awards, 6th, 7th, 8th National Research Paper Competition in Physics |
Professional Memberships
Selected Presentations & Talks
Formal Peers
- 2021. Lysine methyltransferase signaling in lung cancer. Invited. Virtual, US.
- 2021. 8p11 amplified NSD3 histone methyltransferase drives squamous cell lung cancer. Invited. Virtual, US.
- 2021. Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Invited. Virtual, US.
- 2021. Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer. Invited. Virtual, US.
- 2020. Novel animal models of gastric adenocarcinoma. Invited. Virtual1, US.
- 2020. SETD5-coordinated chromatin reprogramming regulates adaptive resistance to targeted pancreatic cancer therapy. Invited. Houston, TX, US.
- 2019. METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis. Invited. Houston, TX, US.
- 2019. Harnessing protein methylation to lung cancer therapy. Invited. Houston, TX, US.
- 2018. Lysine methyltransferase regulation of protein synthesis. Invited. Houston, TX, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Targeting epigenetic vulnerabilities in pancreatic cancer |
| Funding Source: | NIH |
| Role: | PI |
| ID: | R01CA312244 |
| Date: | 2026 - 2031 |
| Title: | Role of eEF1A methylation in oncogenic mRNA decoding |
| Funding Source: | NIH |
| Role: | PI |
| ID: | R01CA313255 |
| Date: | 2026 - Present |
| Title: | Targeting MTAP-deficient solid tumors beyond MTA-cooperative PRMT5 inhibitors |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-PI |
| ID: | Multidisciplinary Research Program (MRP) |
| Date: | 2023 - 2028 |
| Title: | Mechanisms of action and therapeutic targeting of the CARM1-NFIB axis in small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA272843 |
| Date: | 2023 - 2028 |
| Title: | Role of the NSD3 methyltransferase in regulation of lung cancer pathogenesis |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA278940 |
| Date: | 2023 - 2028 |
| Title: | Therapeutic targeting of NSD2 activity in lung adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA272844 |
| Date: | 2022 - 2027 |
| Title: | Tumor cell lineage diversity and composition in gastric cancer progression and therapy resistance |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA266280 |
| Date: | 2022 - 2025 |
| Title: | Identification of oncogenic mechanisms driving lung squamous cell cancer |
| Funding Source: | CIPRIT |
| Role: | PI |
| ID: | RP220391 |
| Date: | 2022 - 2026 |
| Title: | Sponsored research |
| Funding Source: | Sanofi Pharmaceuticals |
| Role: | PI |
| Date: | 2021 - 2022 |
| Title: | Spatiotemporal tumor cell lineage diversity and composition in gastric cancer |
| Funding Source: | MDACC - IRG Basic Research |
| Role: | Co-PI |
| Date: | 2021 - 2023 |
| Title: | Identification and validation of KRAS-MAPK targeted inhibitors synergies |
| Funding Source: | Ikena Oncology |
| Role: | PI |
| Date: | 2021 - 2023 |
| Title: | Exploring the role of epigenetic regulation in gastric cancer progression and therapy resistance |
| Funding Source: | Gastric Cancer Workgroup at MDACC |
| Role: | PI |
| Date: | 2020 - 2021 |
| Title: | Sponsored research |
| Funding Source: | Sanofi Pharmaceuticals |
| Role: | PI |
| Date: | 2019 - 2022 |
| Title: | Transcription Control of Exhaustion Program in CAR T Cell Therapy |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | W81XWH1910761 |
| Date: | 2019 - 2025 |
| Title: | Role of the METTL13 Lysine Methyltransferase in Signaling and Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA236118 |
| Date: | 2019 - 2024 |
| Title: | Role of SETD5 in Chromatin Regulation and Tumorigenesis |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA236949 |
| Date: | 2019 - 2020 |
| Title: | Innovation Award (awarded second time) |
| Funding Source: | Sanofi Pharmaceutical strategic research alliance with MD Anderson Cancer Center |
| Role: | PI |
| ID: | AWD00001115 |
| Date: | 2019 - 2021 |
| Title: | Harnessing protein methylation to lung cancer therapy |
| Funding Source: | Lung Cancer Research Foundation |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Dissecting lysine methyltransferase signaling in pancreatic cancer therapy |
| Funding Source: | American Gastroenterological Association |
| Role: | PI |
| Date: | 2018 - 2020 |
| Title: | Next generation mouse models of pancreatic neuroendocrine tumors |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | PI |
| Date: | 2018 - 2019 |
| Title: | Generation of animal models of acinar cell carcinoma |
| Funding Source: | Infrontier 2020 |
| Role: | PI |
| Date: | 2018 - 2020 |
| Title: | Dissecting molecular pathways driving lung cancer development and drug resistance |
| Funding Source: | MDACC - IRG Basic Research |
| Role: | PI |
| ID: | 2018-00055347-Y1 |
| Date: | 2018 - 2019 |
| Title: | Innovation Award (first award) |
| Funding Source: | Sanofi Pharmaceutical strategic research alliance with MD Anderson Cancer Center |
| Role: | PI |
| ID: | FP00004283 |
| Date: | 2017 - 2018 |
| Title: | UT SPORE in Lung Cancer Enhancement Research |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| ID: | FP00004231 |
| Date: | 2017 - 2018 |
| Title: | Exploring the role of the lysine methyltransferases in small cell lung cancer |
| Funding Source: | MDACC-Small Cell Lung Cancer Workgroup |
| Role: | Principal Investigator-MDACC |
| Date: | 2017 - 2018 |
| Title: | UTMDACC Cancer Center Support (Core) Grant - NFA– NIH: Mechanisms of cancer progression and drug resistance |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| ID: | FP00003646 |
| Date: | 2017 - 2020 |
| Title: | The SMYD3-ERK5 Signaling Module in Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R00CA197816 |
| Date: | 2017 - 2019 |
| Title: | Mechanisms of cancer progression and drug resistance |
| Funding Source: | The University of Texas STARs Award |
| Role: | PI |
| ID: | Rising STARs Award |
| Date: | 2017 - 2021 |
| Title: | Recruitment of First-Time, Tenure-Track Faculty Members |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RR160078 |
Selected Publications
Peer-Reviewed Articles
- Jeong, J, Hausmann, SC, Dong, H, Szczepski, K, Flores, N, Garcia Gonzalez, A, Shi, L, Lu, X, Lempiäinen, J, Jakab, M, Zeng, L, Chasan, T, Bareke, E, Dong, R, Carlson, E, Padilla, R, Husmann, D, Thompson, J, Shipman, GA, Zahn, E, Barnes, CA, Khan, LF, Albertorio-Sáez, LM, Brill, E, Kumary, VS, Marunde, MR, Maryanski, DN, Szany, CC, Venters, BJ, Windham, CL, Nowakowski, ME, Czaban, I, Jaremko, M, Keogh, MC, Le, K, Soth, MJ, Garcia, BA, Jaremko, Ł, Majewski, J, Mazur, PK, Gozani, O. NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers. Nature 649(8095):205-215, 2026. e-Pub 2026. PMID: 40770093.
- Cai, L, Wu, F, Zhou, Q, Gao, Y, Yao, B, Deberardinis, RJ, Acquaah-Mensah, G, Aidinis, V, Beane, J, Biswal, S, Chen, T, Concepcion-Crisol, CP, Grüner, BM, Jia, D, Jones, RA, Kurie, JM, Lee, MG, Lindahl, P, Lissanu, Y, Lorz, C, MacPherson, D, Martinelli, R, Mazur, PK, Mazzilli, SA, Mii, S, Moll, HP, Moorehead, RA, Morrisey, EE, Ng, SR, Oser, M, Pandiri, AR, Powell, CA, Ramadori, G, Santos, M, Snyder, EL, Sotillo, R, Su, KY, Taki, T, Taparra, K, Tran, PT, Xia, Y, Van Veen, JE, Winslow, MM, Xiao, G, Rudin, CM, Oliver, TG, Xie, Y, Minna, J. The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models. Cancer Research 85(10):1769-1783, 2025. e-Pub 2025. PMID: 40298430.
- Park, J, Wu, J, Szkop, KJ, Jeong, J, Jovanovic, P, Husmann, D, Flores, N, Francis, JW, Chen, YJ, Benitez, AM, Zahn, E, Song, S, Ajani, JA, Wang, L, Singh, K, Larsson, O, Garcia, BA, Topisirovic, I, Gozani, O, Mazur, PK. SMYD5 methylation of rpL40 links ribosomal output to gastric cancer. Nature 632(8025):656-663, 2024. e-Pub 2024. PMID: 39048817.
- Miao, B, Ge, L, He, C, Wang, X, Wu, J, Li, X, Chen, K, Wan, J, Xing, S, Ren, L, Shi, Z, Liu, S, Hu, Y, Chen, J, Yu, Y, Feng, L, Flores, NM, Liang, Z, Xu, X, Wang, R, Zhou, J, Fan, J, Xiang, B, Li, E, Mao, Y, Cheng, J, Zhao, K, Mazur, PK, Cai, J, Lan, F. SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma. Cell research 34(9):648-660, 2024. e-Pub 2024. PMID: 39103523.
- Casanova, AG, Roth, GS, Hausmann, SC, Lu, X, Bischoff, LJ, Froeliger, EM, Belmudes, L, Bourova-Flin, E, Flores, N, Benitez, AM, Chasan, T, Caporicci, M, Vayr, J, Blanchet, S, Ielasi, F, Rousseaux, S, Hainaut, P, Gozani, O, Le Romancer, M, Couté, Y, Palencia, A, Mazur, PK, Reynoird, N. Cytoskeleton remodeling induced by SMYD2 methyltransferase drives breast cancer metastasis. Cell Discovery 10(1), 2024. e-Pub 2024. PMID: 38296970.
- Cheng X, Dai E, Wu J, Flores NM, Chu Y, Wang R, Dang M, Xu Z, Han G, Liu Y, Chatterjee D, Hu C, Ying J, Du Y, Yang L, Guan X, Mo S, Cao X, Pei G, Jiang J, Lu X, Benitez AM, Waters RE, Pizzi MP, Shanbhag N, Fan Y, Peng F, Hanash SM, Calin G, Futreal A, Song S, Yee C, Mazur PK, Qin JJ, Ajani JA, Wang L. Atlas of Metastatic Gastric Cancer Links Ferroptosis to Disease Progression and Immunotherapy Response. Gastroenterology 167(7):1345-1357, 2024. e-Pub 2024. PMID: 39097198.
- Francis, JW, Hausmann, SC, Ikram, S, Yin, K, Mealey-Farr, R, Flores, N, Trinh, AT, Chasan, T, Thompson, J, Mazur, PK, Gozani, O. FAM86A methylation of eEF2 links mRNA translation elongation to tumorigenesis. Molecular cell 84(9):1753-1763.e7, 2024. e-Pub 2024. PMID: 38508183.
- Fuentes, ME, Lu, X, Flores, N, Hausmann, SC, Mazur, PK. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 38609433.
- Lu, X, Lofgren, SM, Zhao, Y, Mazur, PK. Multiplexed transcriptomic profiling of the fate of human CAR T cells in vivo via genetic barcoding with shielded small nucleotides. Nature Biomedical Engineering 7(9):1170-1187, 2023. e-Pub 2023. PMID: 37652986.
- Xu C, Huang KK, Law JH, Chua JS, Sheng T, Flores NM, Pizzi MP, Okabe A, Tan ALK, Zhu F, Kumar V, Lu X, Benitez AM, Lian BSX, Ma H, Ho SWT, Ramnarayanan K, Anene-Nzelu CG, Razavi-Mohseni M, Abdul Ghani SAB, Tay ST, Ong X, Lee MH, Guo YA, Ashktorab H, Smoot D, Li S, Skanderup AJ, Beer MA, Foo RSY, Wong JSH, Sanghvi K, Yong WP, Sundar R, Kaneda A, Prabhakar S, Mazur PK, Ajani JA, Yeoh KG, So JB, Tan P, Cancer Consortium SG. Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Gut 72(9):1651-1663, 2023. e-Pub 2023. PMID: 36918265.
- Wang, R, Song, S, Qin, JJ, Yoshimura, K, Peng, F, Chu, Y, Li, Y, Fan, Y, Jin, J, Dang, M, Dai, E, Pei, G, Han, G, Hao, D, Li, Y, Chatterjee, D, Harada, K, Pizzi, MP, Scott, AW, Tatlonghari, G, Yan, X, Xu, Z, Hu, C, Mo, S, Shanbhag, N, Lu, Y, Sewastjanow-Silva, M, Fouad Abdelhakeem, AA, Peng, G, Hanash, SM, Calin, GA, Yee, C, Mazur, PK, Marsden, AN, Futreal, A, Wang, Z, Cheng, XD, Ajani, JA, Wang, L. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer cell 41(8):1407-1426.e9, 2023. e-Pub 2023. PMID: 37419119.
- Mealey-Farr R, Jeong J, Park J, Liu S, Hausmann S, Francis JW, Angulo Ibanez M, Cho J, Chua K, Mazur PK, Gozani O. Antibody toolkit to investigate eEF1A methylation dynamics in mRNA translation elongation. J Biol Chem 299(6):104747, 2023. e-Pub 2023. PMID: 37094697.
- Fan Y, Li Y, Yao X, Jin J, Scott A, Liu B, Wang S, Huo L, Wang Y, Wang R, Pool Pizzi M, Ma L, Shao S, Sewastjanow-Silva M, Waters R, Chatterjee D, Liu B, Shanbhag N, Peng G, Calin GA, Mazur PK, Hanash SM, Ishizawa J, Hirata Y, Nagano O, Wang Z, Wang L, Xian W, McKeon F, Ajani JA, Song S. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment. Gut 72(4):624-637, 2023. e-Pub 2023. PMID: 36002248.
- Mello SS, Flowers BM, Mazur PK, Lee JJ, Müller F, Denny SK, Ferreira S, Hanson K, Kim SK, Greenleaf WJ, Wood LD, Attardi LD. Multifaceted role for p53 in pancreatic cancer suppression. Proc Natl Acad Sci U S A 120(10):e2211937120, 2023. e-Pub 2023. PMID: 36848578.
- Gao G, Hausmann S, Flores NM, Benitez AM, Shen J, Yang X, Person MD, Gayatri S, Cheng D, Lu Y, Liu B, Mazur PK, Bedford MT. The NFIB/CARM1 partnership is a driver in preclinical models of small cell lung cancer. Nat Commun 14(1):363, 2023. e-Pub 2023. PMID: 36690626.
- Lukinovic V, Hausmann S, Roth GS, Oyeniran C, Ahmad T, Tsao N, Brickner JR, Casanova AG, Chuffart F, Benitez AM, Vayr J, Rodell R, Tardif M, PWTC J, Couté Y, Vermeulen M, Hainaut P, Mazur PK, Mosammaparast N, Reynoird N. SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation-Phosphorylation Cross-talk. Cancer Discov 12(9):2158-2179, 2022. e-Pub 2022. PMID: 35819319.
- Sengupta D, Zeng L, Li Y, Hausmann S, Ghosh D, Yuan G, Nguyen TN, Lyu R, Caporicci M, Morales Benitez A, Coles GL, Kharchenko V, Czaban I, Azhibek D, Fischle W, Jaremko M, Wistuba II, Sage J, Jaremko L, Li W, Mazur PK, Gozani O. NSD2 dimethylation at H3K36 promotes lung adenocarcinoma pathogenesis. Mol Cell 81(21):4481-4492.e9, 2021. e-Pub 2021. PMID: 34555356.
- Hessmann, E, Schneider, G, Bousquet, C, Der, CJ, Dreyer, S, Dusetti, NJ, Eilers, M, Ellenrieder, V, Espinet, E, Falcomatà, C, Feldmann, K, Gebhardt, A, Gress, TM, Hamdan, F, Huber, M, Johnsen, SA, Kleger, A, Krenz, B, Lomberk, G, Mazur, PK, Michl, P, Morton, JP, Pasca di Magliano, M, Picard, F, Reichert, M, Saur, D, Schmid, RM, Sebens, S, Singh, SK, Siveke, J, Trumpp, A. New Insights Into Pancreatic Cancer. Gastroenterology 161(3):785-791, 2021. e-Pub 2021. PMID: 34089734.
- Yuan G, Flores NM, Hausmann S, Lofgren SM, Kharchenko V, Angulo-Ibanez M, Sengupta D, Lu X, Czaban I, Azhibek D, Vicent S, Fischle W, Jaremko M, Fang B, Wistuba II, Chua KF, Roth JA, Minna JD, Shao NY, Jaremko L, Mazur PK, Gozani O. Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature 590(7846):504-508, 2021. e-Pub 2021. PMID: 33536620.
- Wang Z, Hausmann S, Lyu R, Li TM, Lofgren SM, Flores NM, Fuentes ME, Caporicci M, Yang Z, Meiners MJ, Cheek MA, Howard SA, Zhang L, Elias JE, Kim MP, Maitra A, Wang H, Bassik MC, Keogh MC, Sage J, Gozani O, Mazur PK. SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. Cancer Cell 37(6):834-849.e13, 2020. e-Pub 2020. PMID: 32442403.
- Valencia K, Erice O, Kostyrko K, Hausmann S, Guruceaga E, Tathireddy A, Flores NM, Sayles LC, Lee AG, Fragoso R, Sun TQ, Vallejo A, Roman M, Entrialgo-Cadierno R, Migueliz I, Razquin N, Fortes P, Lecanda F, Lu J, Ponz-Sarvise M, Chen CZ, Mazur PK, Sweet-Cordero EA, Vicent S. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas. J Clin Invest 130(4):1879-1895, 2020. e-Pub 2020. PMID: 31874105.
- Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J, Li A, Nguyen ND, Caporicci M, Kim MP, Maitra A, Wang H, Wistuba II, Porco JA, Bassik MC, Elias JE, Song J, Topisirovic I, Van Rechem C, Mazur PK, Gozani O. METTL13 Methylation of eEF1A Increases Translational Output to Promote Tumorigenesis. Cell 176(1):491-504, 2019. e-Pub 2019. PMID: 30612740.
- Mello SS, Sinow C, Raj N, Mazur PK, Bieging-Rolett K, Broz DK, Imam JFC, Vogel H, Wood LD, Sage J, Hirose T, Nakagawa S, Rinn J, Attardi LD. Neat1 is a p53-inducible lincRNA essential for transformation suppression. Genes Dev 31(11):1095-1108, 2017. e-Pub 2017. PMID: 28698299.
- Vallejo A, Perurena N, Guruceaga E, Mazur PK, Martinez-Canarias S, Zandueta C, Valencia K, Arricibita A, Gwinn D, Sayles LC, Chuang CH, Guembe L, Bailey P, Chang DK, Biankin A, Ponz-Sarvise M, Andersen JB, Khatri P, Bozec A, Sweet-Cordero EA, Sage J, Lecanda F, Vicent S. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nat Commun 8:14294, 2017. e-Pub 2017. PMID: 28220783.
- Jahchan NS, Lim JS, Bola B, Morris K, Seitz G, Tran KQ, Xu L, Trapani F, Morrow CJ, Cristea S, Coles GL, Yang D, Vaka D, Kareta MS, George J, Mazur PK, Nguyen T, Anderson WC, Dylla SJ, Blackhall F, Peifer M, Dive C, Sage J. Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. Cell Rep 16(3):644-56, 2016. e-Pub 2016. PMID: 27373157.
- Reynoird N, Mazur PK, Stellfeld T, Flores NM, Lofgren SM, Carlson SM, Brambilla E, Hainaut P, Kaznowska EB, Arrowsmith CH, Khatri P, Stresemann C, Gozani O, *equally contributed SJ. Coordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer. Genes Dev 30(7):772-85, 2016. e-Pub 2016. PMID: 26988419.
- Krampitz GW, George BM, Willingham SB, Volkmer JP, Weiskopf K, Jahchan N, Newman AM, Sahoo D, Zemek AJ, Yanovsky RL, Nguyen JK, Schnorr PJ, Mazur PK, Sage J, Longacre TA, Visser BC, Poultsides GA, Norton JA, Weissman IL. Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors. Proc Natl Acad Sci U S A 113(16):4464-9, 2016. e-Pub 2016. PMID: 27035983.
- Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sánchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, Trajkovic-Arsic M, Gupta A, Heid I, Noël PB, Braren R, Erkan M, Kleeff J, Sipos B, Sayles LC, Heikenwalder M, Heßmann E, Ellenrieder V, Esposito I, Jacks T, Bradner JE, Khatri P, Sweet-Cordero EA, Attardi LD, Schmid RM, Schneider G, Sage J, Siveke JT. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat Med 21(10):1163-71, 2015. e-Pub 2015. PMID: 26390243.
- Baumgart A, Mazur PK, Anton M, Rudelius M, Schwamborn K, Feuchtinger A, Behnke K, Walch A, Braren R, Peschel C, Duyster J, Siveke JT, Dechow T. Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model. Oncogene 34(5):578-88, 2015. e-Pub 2015. PMID: 24509876.
- Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, Tummino PJ, Kruger RG, Garcia BA, Butte AJ, Vermeulen M, Sage J, Gozani O. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 510(7504):283-7, 2014. e-Pub 2014. PMID: 24847881.
- Chen R, Khatri P, Mazur PK, Polin M, Zheng Y, Vaka D, Hoang CD, Shrager J, Xu Y, Vicent S, Butte AJ, Sweet-Cordero EA. A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma. Cancer Res 74(10):2892-902, 2014. e-Pub 2014. PMID: 24654231.
- Jahchan NS, Dudley JT, Mazur PK, Flores N, Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M, Krasinska K, Riess JW, Neal JW, Khatri P, Park KS, Butte AJ, Sage J. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov 3(12):1364-77, 2013. e-Pub 2013. PMID: 24078773.
- Jameson KL, Mazur PK, Zehnder AM, Zhang J, Zarnegar B, Sage J, Khavari PA. IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat Med 19(5):626-30, 2013. e-Pub 2013. PMID: 23603816.
- Ardito CM, Grüner BM, Takeuchi KK, Lubeseder-Martellato C, Teichmann N, Mazur PK, Delgiorno KE, Carpenter ES, Halbrook CJ, Hall JC, Pal D, Briel T, Herner A, Trajkovic-Arsic M, Sipos B, Liou GY, Storz P, Murray NR, Threadgill DW, Sibilia M, Washington MK, Wilson CL, Schmid RM, Raines EW, Crawford HC, Siveke JT. EGF receptor is required for KRAS-induced pancreatic tumorigenesis. Cancer Cell 22(3):304-17, 2012. e-Pub 2012. PMID: 22975374.
- Aichler M, Seiler C, Tost M, Siveke J, Mazur PK, Da Silva-Buttkus P, Bartsch DK, Langer P, Chiblak S, Dürr A, Höfler H, Klöppel G, Müller-Decker K, Brielmeier M, Esposito I. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues. J Pathol 226(5):723-34, 2012. e-Pub 2012. PMID: 21984419.
- Mazur PK, Riener MO, Jochum W, Kristiansen G, Weber A, Schmid RM, Siveke JT. Expression and clinicopathological significance of notch signaling and cell-fate genes in biliary tract cancer. Am J Gastroenterol 107(1):126-35, 2012. e-Pub 2012. PMID: 21931375.
- Grüner BM, Hahne H, Mazur PK, Trajkovic-Arsic M, Maier S, Esposito I, Kalideris E, Michalski CW, Kleeff J, Rauser S, Schmid RM, Küster B, Walch A, Siveke JT. MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancer. PLoS One 7(6):e39424, 2012. e-Pub 2012. PMID: 22761793.
- Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, Vogel H, Sylvester KG, Thorgeirsson SS, Grompe M, Sage J. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med 208(10):1963-76, 2011. e-Pub 2011. PMID: 21875955.
- Heid I, Lubeseder-Martellato C, Sipos B, Mazur PK, Lesina M, Schmid RM, Siveke JT. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology 141(2):719-30, 730.e1-7, 2011. e-Pub 2011. PMID: 21684285.
- Mazur PK, Grüner BM, Nakhai H, Sipos B, Zimber-Strobl U, Strobl LJ, Radtke F, Schmid RM, Siveke JT. Identification of epidermal Pdx1 expression discloses different roles of Notch1 and Notch2 in murine Kras(G12D)-induced skin carcinogenesis in vivo. PLoS One 5(10):e13578, 2010. e-Pub 2010. PMID: 21042537.
- Mazur PK, Einwächter H, Lee M, Sipos B, Nakhai H, Rad R, Zimber-Strobl U, Strobl LJ, Radtke F, Klöppel G, Schmid RM, Siveke JT. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 107(30):13438-43, 2010. e-Pub 2010. PMID: 20624967.
- Nakhai H, Siveke JT, Klein B, Mendoza-Torres L, Mazur PK, Algül H, Radtke F, Strobl L, Zimber-Strobl U, Schmid RM. Conditional ablation of Notch signaling in pancreatic development. Development 135(16):2757-65, 2008. e-Pub 2008. PMID: 18635610.
- Geisler F, Nagl F, Mazur PK, Lee M, Zimber-Strobl U, Strobl LJ, Radtke F, Schmid RM, Siveke JT. Liver-specific inactivation of Notch2, but not Notch1, compromises intrahepatic bile duct development in mice. Hepatology 48(2):607-16, 2008. e-Pub 2008. PMID: 18666240.
- Siveke JT, Lubeseder-Martellato C, Lee M, Mazur PK, Nakhai H, Radtke F, Schmid RM. Notch signaling is required for exocrine regeneration after acute pancreatitis. Gastroenterology 134(2):544-55, 2008. e-Pub 2008. PMID: 18242220.
Invited Articles
- Hester R, Mazur PK, McAllister F. Immunotherapy in Pancreatic Adenocarcinoma: Beyond "Copy/Paste". Clin Cancer Res 27(23):6287-6297, 2021. e-Pub 2021. PMID: 34193514.
- Mazur PK, Gozani O, Sage J, Reynoird N. Novel insights into the oncogenic function of the SMYD3 lysine methyltransferase. Transl Cancer Res 5(3):330-333, 2016. e-Pub 2016. PMID: 30713830.
Review Articles
- Jagielski T, van Ingen J, Rastogi N, Dziadek J, Mazur PK, Bielecki J. Current methods in the molecular typing of Mycobacterium tuberculosis and other mycobacteria. Biomed Res Int 2014:645802, 2014. e-Pub 2014. PMID: 24527454.
- Mazur PK, Siveke JT. Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. Gut 61(10):1488-500, 2012. e-Pub 2012. PMID: 21873467.
Editorials
- Mazur PK, Sage J. Pancreatic cancer takes its Toll. J Exp Med 212(12):1988, 2015. PMID: 26573583.
Book Chapters
- Mazur PK, Herner A, Neff F, Siveke JT. Current methods in mouse models of pancreatic cancer. In: Methods Mol Biol, 185-215, 2015.
- Lu X, Lofgren SM, Liyong Z Mazur PK. An image based high-throughput assay to quantify CAR-T cell cytotoxicity. In: Methods in Molecular Biology. Springer Nature.
Patents
- Shielded small nucleotides for intracellular barcoding, 2022. Patent Number: PCT/US2022/078994.
Patient Reviews
CV information above last modified July 22, 2026